medigraphic.com

2004, Number 4

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2004; 42 (4)

Metformin and the Free Fatty Acids: Clinical Study

Sabido SA, Castañeda AI, González PR, Morales GMI, Cigarroa BM, Figueroa HRS

Language: Spanish
References: 30
Page: 285-292
PDF size: 173.73 Kb.


ABSTRACT

Introduction: metformin can reduce free fatty acid levels (FFA), this subtrates are implicated in the metabolic disturbances of diabetes mellitus and obesity; in clinical practice insulin resistance and glucose metabolism was reduced, although the mechanisms by which its effect is exerted are not completely investigated todate.
Objective: to examine the manner in which impro-vement in FFA plasma levels might contribute to metformin’s antidiabetic activity in glucose-intolerant obese subjects.
Material and methods: forty glucose-intolerant subjects received, in the experimental group, merformin 850 mg twice a day (n = 19) or the con-trol group, placebo (n = 21) for 6 months in a random double-blind trial. Free fatty acids, insulin resistance, and Β cell function were quantified with homeostasis model.
Results: metformin reduced plasma free fatty acids from 1.04 to 0.41 mEq/L, p ‹ 0.003; and Β cell function improved from 157 to 181, p = 0.043. The free fatty acid reduction correlated with glucose reduction (r2 = 0.251), insulin resistance (r2 = 0.628), and with improvement in Β cell function (r2 = 0.55).
Conclusions: improvement in FFA plasma levels by metformin drug might contribute to glucose reduction in 25 %, insulin resistance in 62 %, and restores insulin secretion in 55 %.


REFERENCES

  1. 1. Bayley C. Biguanides and NIDD. Diabetes Care 1992;15(6):755-771.

  2. 2. Kilp A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care 1993;13:696-704.

  3. 3. Galuska D, Zierath J, Thorne A, Sonnenfeld, Walberg-Henriksson H. Metformin increase insulin stimu-lated glucose transport in insulin-resistant human skeletal muscle. Diabetes Meta 1991;17:159-163.

  4. 4. Perriello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferrannini E, et al. Acute antihyper-glycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994;43:929-928.

  5. 5. Abbasi F, Carantoni M, Kamath V, Rizvi A, Chen Y-D, Reaven G. Results of a placebo-controlled study of the metabolic effect of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue. Diabetes Care 1997;20 (12)1863-1869.

  6. 6. Gordon ES. Non-esterifies fatty acids in blood of obese and lean subjects. Am J Clin Nutr 1960;8: 740-789.

  7. 7. Boden G. Role of fatty acids in the patogenesis of insulin resistance and NIDDM. Diabetes 1996;45:3-10.

  8. 8. Randle OJ, Hales CN, Garland PV, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin insensi-tivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;I:785-789.

  9. 9. Sakao Y, Dua VE. A 48 hours lipid infusion in the rat time dependently inhibits glucose induced insulin secretion and b cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology 1990;127:1582-1589.

  10. Hanes M, Dua A, Kaissebah AH. Effect of free fatty acid and glucose on splanchnic insulin dynamic. Diabetes 1997;46:57-62.

  11. Lioja S, Mott DM, Howard BV, Bennett PH, Yki-Järvinen H, Freymond D, et al. Impaired glucose tolerance as disorder of insulin action. N Engl J Med 1988;318:1217-1225.

  12. Keen H, Jarrett RJ, MacCarteney P. Then-year follow-up of the Bedford Survey (1962-1997): glucose tolerance and diabetes. Diabetologia 1982; 22:76-78.

  13. Harrett RJ, MacCartney P, Keen H. The Bedford Survey: ten year mortality rates in newly diagnosis diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia 1982;22:79-84.

  14. Lehtovirta M, Forsen B, Gullstrom M, Haggblom M, Eriksson JG, Taskinen MR, Groop L. Metabolic effects of metformin in patients with impaired glucose tolerance. Diabet Med 2001;18(7):578-83.

  15. Grosskope I, Ringel Y, Charach G, Maharshak N, Mor R, et al. Metformin enhances clearance of chylomicrons and chylomicron remnants in nondiabetic mild overweight glucose-intolerant subjects. Diabetes Care 1997;20:1598-1602.

  16. Fontbonne A, Charles MA, Vague J. André P, Isnard F, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distri-bution. Diabetes Care 1996;19:920-926.

  17. Patane G, Piro S, Rabuazzo AM, Anello M, Vigneri R. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta cells. Diabetes 2000;49(5):735-740.

  18. Song S, Andrikopoulos S, Filippis C, Thorburn AW. Mechanism of fat-induced hepatic gluco-neogenesis: effect of metformin. Am J Physiol Endocrinol Metab 2001;281(2):E275-E282.

  19. Morel Y, Golay A, Perneger T, Lehmann T, Vadas L, et al. Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance. Diabet Med 1999;16(8):650-655.

  20. Dietary Assessment Resource Manual. American Institute of Nutrition. 1994;(Suppl 1):2245S- 2327S.

  21. Rabasa-Lhoret R, Laville M. How to measure insulin sensitivity in clinical practice? Diabetes Metab 2001;27(2 Pt 2):201-208.

  22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and b cell function from fasting plasma glucose and insulin concen-trations in man. Diabetologia 1985;28:412-419.

  23. Haffener SM, González C. Miettinen H, Kennedy E, Sterrn MP. A prospective analysis of the HOMA model (The Mexico City Diabetes Study). Diabetes Care 1996;19(10):1138-1141.

  24. Vázquez CC, Salinas OS, Gómez DRA, Rosso JMM, et al. ¿Cuál es el nivel de insulina en una po-blación mexicana en peso ideal? Rev Edocrinol Nutr 2003; 11(1):22-27.

  25. Hupponen R. Determination of metformin in plasma by high-performance liquid chromatography. J Chromatogr 1992;583:270-273.

  26. Lehtovirta M, Forsen B, Gullstrom M, Haggblom M, Eriksson JG, Taskinen MR, Groop L. Metabolic effects of metformin in patients with impaired glucose tolerance. Diabet Med 2001;18(7):578-583.

  27. Gregorio F, Ambrosi F, Manfrini S, Santucci A, Filipponi P. Meformin, plasma glucose and free fatty acids in type II diabetic out-patients: results of a clinical study. Diabetes Res Clin Pract 1997;37(1):21-33.

  28. Li Cl, Pan CI, Lu JM, Zhu Y, Wang JH, Deng XX, et al. Effect of metformin on patients with impaired glucose tolerance. Diabet Med 1999;16(6):477-481.

  29. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA. Reduction in the incidence of type 2 diabetes with lifestyle inter-vention or metformin. N Engl J Med 2002;346(6): 393-403.

  30. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1283-1197.




2020     |     www.medigraphic.com